Spectaire (SPEC) Competitors $0.05 +0.00 (+7.78%) (As of 12:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends SPEC vs. TLIS, TBIO, THMO, OLITW, PRENW, QSIAW, SMAPW, TT, KEYS, and FTVShould you be buying Spectaire stock or one of its competitors? The main competitors of Spectaire include Talis Biomedical (TLIS), Telesis Bio (TBIO), ThermoGenesis (THMO), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), Quantum-Si (QSIAW), SportsMap Tech Acquisition (SMAPW), Trane Technologies (TT), Keysight Technologies (KEYS), and Fortive (FTV). These companies are all part of the "measuring and control equipment" industry. Spectaire vs. Talis Biomedical Telesis Bio ThermoGenesis OmniLit Acquisition Prenetics Global Quantum-Si SportsMap Tech Acquisition Trane Technologies Keysight Technologies Fortive Talis Biomedical (NASDAQ:TLIS) and Spectaire (NASDAQ:SPEC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability. Which has more volatility and risk, TLIS or SPEC? Talis Biomedical has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Spectaire has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Which has better valuation & earnings, TLIS or SPEC? Spectaire has lower revenue, but higher earnings than Talis Biomedical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalis Biomedical$2.13M1.44-$62.01M-$28.02-0.06SpectaireN/AN/A$8.95MN/AN/A Does the MarketBeat Community favor TLIS or SPEC? Talis Biomedical received 9 more outperform votes than Spectaire when rated by MarketBeat users. Likewise, 37.50% of users gave Talis Biomedical an outperform vote while only 0.00% of users gave Spectaire an outperform vote. CompanyUnderperformOutperformTalis BiomedicalOutperform Votes937.50% Underperform Votes1562.50% SpectaireOutperform VotesNo VotesUnderperform Votes1100.00% Is TLIS or SPEC more profitable? Spectaire has a net margin of 0.00% compared to Talis Biomedical's net margin of -5,784.73%. Talis Biomedical's return on equity of -79.74% beat Spectaire's return on equity.Company Net Margins Return on Equity Return on Assets Talis Biomedical-5,784.73% -79.74% -57.16% Spectaire N/A -81.22%304.57% Do insiders & institutionals hold more shares of TLIS or SPEC? 43.8% of Talis Biomedical shares are held by institutional investors. Comparatively, 26.6% of Spectaire shares are held by institutional investors. 46.0% of Talis Biomedical shares are held by insiders. Comparatively, 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor TLIS or SPEC? In the previous week, Talis Biomedical's average media sentiment score of 0.00 equaled Spectaire'saverage media sentiment score. Company Overall Sentiment Talis Biomedical Neutral Spectaire Neutral SummaryTalis Biomedical beats Spectaire on 7 of the 10 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Spectaire News Delivered to You Automatically Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPEC vs. The Competition Export to ExcelMetricSpectaireMeasuring & controlling devices IndustryComputer SectorNASDAQ ExchangeMarket Cap$893,000.00$18.42B$23.86B$8.81BDividend YieldN/A3.23%2.76%4.07%P/E RatioN/A12.58234.2514.18Price / SalesN/A16.653,482.4788.10Price / Cash0.0715.4733.0836.27Price / Book-0.032.906.886.35Net Income$8.95M$505.59M$659.20M$225.71M7 Day PerformanceN/A4.97%1.04%-0.32%1 Month PerformanceN/A5.63%1.71%1.76%1 Year PerformanceN/A10.09%20.15%27.70% Spectaire Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPECSpectaireN/A$0.05+7.8%N/A-97.8%$893,000.00N/A0.008Gap UpTLISTalis BiomedicalN/A$1.69-1.4%N/A-76.1%$3.08M$2.13M0.00260TBIOTelesis BioN/A$0.90-5.3%N/A-86.5%$1.60M$27.51M0.00200Gap DownTHMOThermoGenesisN/A$0.00flatN/A-100.0%$4,000.00$9.44M0.0025OLITWOmniLit AcquisitionN/A$0.04-20.0%N/A-49.9%$0.00N/A0.003Gap DownPRENWPrenetics GlobalN/A$0.01-13.0%N/A+0.0%$0.00$22.66M0.001QSIAWQuantum-SiN/A$0.16+33.5%N/A-52.0%$0.00$1.70M0.00159High Trading VolumeSMAPWSportsMap Tech AcquisitionN/A$0.03+40.7%N/A-1.7%$0.00N/A0.00N/AGap DownTTTrane Technologies4.1119 of 5 stars$417.41+1.5%$389.77-6.6%+81.2%$93.93B$17.68B38.1440,000Positive NewsKEYSKeysight Technologies4.5709 of 5 stars$169.77+2.6%$177.30+4.4%+22.7%$29.46B$4.98B47.2814,900Analyst ForecastOptions VolumeNews CoverageFTVFortive4.8979 of 5 stars$76.47+1.0%$87.82+14.8%+11.9%$26.53B$6.07B30.3718,000Analyst Forecast Related Companies and Tools Related Companies TLIS Alternatives TBIO Alternatives THMO Alternatives OLITW Alternatives PRENW Alternatives QSIAW Alternatives SMAPW Alternatives TT Alternatives KEYS Alternatives FTV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPEC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectaire Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spectaire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
